Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Verichem Enzyme ER Calibration Verifier kit

March 2023—Verichem Laboratories’ ready-to-use Enzyme ER Calibration Verifier kit is now available. The materials are designed for the calibration verification of enzyme assays on wet chemistry testing systems and contain nine clinical enzyme components covering 54 individual activity levels. The enzyme components within the materials include amylase, alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, cholinesterase, creatine phosphokinase, gamma glutamyltransferase, lactate dehydrogenase, and lipase. The materials are intended to be treated as patient specimens and have a shelf life of 18 months.

 

Qiagen, Sophia partner to offer NGS solutions

March 2023—Qiagen has launched its QIAseq Platform Partnership program and a partnership with Sophia Genetics that will bring together QIAseq reagent technology for next-generation sequencing with the Sophia DDM digital analytics platform. The Platform Partnership program aims to enhance the use and compatibility of QIAseq NGS kits to support secondary analysis and tertiary interpretation workflows offered by other digital data-sharing and analytics companies. The kits are designed for use with any sequencer.

 

NRichDx products for developing liquid biopsy assays

March 2023—NRichDx has launched two products for developing liquid biopsy assays. The IVD-labeled NRichDx Revolution Circulating Free Total Nucleic Acid kit is used for extracting circulating cell-free total nucleic acid and comes in two kit sizes for sample volumes ranging from 1 to 20 mL.

 

LGC launches BRCA1/2 reference materials

March 2023—LGC Clinical Diagnostics has launched the Seraseq gDNA BRCA1/2 LGR Somatic Mutation Mix and Seraseq gDNA BRCA1/2 LGR Inherited Mutation Mix. The products are intended for use as quality reference materials in developing, validating, and evaluating the routine performance of laboratory tests and are for research use only.

 

FDA expands approval of BD Onclarity HPV assay

March 2023—BD announced FDA market approval for the Onclarity HPV assay to be used with the Hologic ThinPrep Pap test. The Onclarity HPV assay detects and identifies 14 high-risk human papillomavirus types in a single analysis. The assay reports genotypes 16, 18, 31, 45, 51, 52, 33/58, 35/39/68, and 56/59/66, and has FDA approval for use in vaccinated women.

 

PerkinElmer debuts NGS workstation

March 2023—PerkinElmer debuted its Zephyr G3 NGS iQ workstation at the Society for Laboratory Automation and Screening conference in San Diego, Feb. 25–March 1. The system enables the automated construction of up to 96 NGS libraries and is composed of a high-performing liquid handler, integrated thermocycler, robotic arm, and deck accessories and peripherals. The workstation is available with an optional cloud-based software to further simplify creating and editing NGS protocols, the company says, by using a single pane of glass interface and developing methods from scientific intent rather than code.

Flagship, Genomenon partnership

March 2023—Flagship Biosciences announced a partnership with Genomenon in which Genomenon’s Mastermind knowledge base will provide disease-specific genomic data sets to enrich Flagship’s genomic profiling services. The partnership aims to accelerate biomarker discovery and companion diagnostics development solutions and improve patient stratification for clinical trials and treatment selection.

 

SeraCare releases HRD reference materials

March 2023—LGC SeraCare has developed three contrived, tumor normal cell-line–derived homologous recombinant deficiency reference materials: Seraseq FFPE HRD High-Positive RM, Seraseq FFPE HRD Low-Positive RM, and Seraseq FFPE HRD Negative RM.

 

Agilent releases on-deck thermal cycler for Bravo NGS platform

March 2023—Agilent Technologies released an on-deck thermal cycler that integrates with the company’s Bravo NGS automated liquid handling platform. The optional acces­sory enables the Bravo platform to provide thermal cycling as part of an automated protocol and extends walkaway time. The setup is beneficial, the company says, for applications such as library preparation and target enrichment steps in next-generation sequencing workflows, end-point PCR, and cell-based applications.

 

Bio-Rad launches real-time PCR system

March 2023—Bio-Rad launched its CFX Opus Deepwell Dx real-time PCR system, an open platform for developing in vitro diagnostic assays. The system multiplexes up to five targets and allows reaction volumes up to 125 µL in a 96-well format for quantitative PCR diagnostic assays. CFX Maestro Dx SE software provides data management and analysis tools.

 

MARKETPLACE

TRENDING